BRCA2 and breast carcinoma: Poly(ADP-ribose) polymerase (PARP) inhibition is used in the clinic to kill HR-deficient tumor cells such as cells mutated for the breast cancer predisposition genes BRCA1 or BRCA2 by synthetic lethality [89].